Kairos Pharma, LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Kairos Pharma, LTD. as of June 30, 2025.
AMEX
Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% beneficial ownership stake in Kairos Pharma, LTD., holding 1,696,924 shares of common stock.